Last updated: July 27, 2026
Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., case number 1:15-cv-00979, is a U.S. Hatch-Waxman patent dispute brought in federal court in 2015. The matter centers on whether Mylan’s proposed generic product infringes and/or is protected by statutory patent carve-outs asserted by Noven. Public docket activity, including case initiation and subsequent filings, is the primary source for timing and procedural posture in the absence of a complete merits record in the provided inputs.
What happened in Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. (1:15-cv-00979)?
The suit was filed in 2015 and proceeded under the Hatch-Waxman framework, which typically pairs with an ANDA filing and one or more patent certifications under 21 U.S.C. § 355(j)(2)(A)-(C).
What is the procedural posture of 1:15-cv-00979?
Key litigation milestones cannot be stated precisely from the provided information because the case-caption number alone does not include docket dates, court orders, or the asserted patent list. A litigation summary requires the docket’s operative documents (complaint, answer, claim construction orders, summary judgment rulings, and final judgment).
What claims and defenses are normally at issue in Hatch-Waxman cases like this?
For this case type, the core dispute usually includes:
- Infringement of one or more Orange Book-listed patents, often including formulation, composition, method-of-use, and/or manufacturing method claims.
- Validity challenges typically raised via non-infringement, anticipation/obviousness arguments, and statutory eligibility attacks.
- Whether the generic’s Paragraph IV (or equivalent) certifications require a stay, and whether any exclusivity periods constrain market entry.
Which patents did Noven assert against Mylan in 1:15-cv-00979?
A definitive patent list cannot be produced from the provided inputs. Patent identification for this docket requires the asserted claims in the complaint or an indexing entry tying the case to an Orange Book reference product and listed patent numbers.
How to map the asserted estate to typical claim categories
For business analysis, Hatch-Waxman disputes involving branded drugs typically split into:
- Composition/formulation patents (e.g., specific ratios, excipient systems, solid-state forms, particle-size or dissolution-related parameters).
- Method-of-use patents (e.g., dosing regimens, patient populations, titration methods).
- Manufacturing method patents (e.g., process steps that control critical quality attributes).
- Device or delivery system patents if the reference product uses a proprietary administration mechanism.
Without the complaint’s “Patent(s)-In-Suit” section, mapping is not actionable.
What Orange Book status applies to the reference listed drug in 1:15-cv-00979?
Orange Book status depends on:
- The specific reference listed drug tied to the ANDA at issue.
- The patent numbers listed for that RLD.
- The statutory exclusivities (NCE, 3-year, 7-year) and any pediatric exclusivity extensions.
The case number does not identify the RLD in the provided content, so Orange Book status and exclusivity timelines cannot be reliably stated.
When does Mylan’s proposed generic entry face patent expiration risk from this case?
Patent expiration and launch timing are driven by:
- The “patent-in-suit” expiration dates.
- Any court stay or negotiated settlement terms that delay entry.
- Whether the court’s final disposition permits entry notwithstanding invalidity findings.
No expiration or settlement-trigger details are provided in the inputs. A launch-risk timeline requires either the final judgment date or the settlement agreement terms (often filed on the docket), plus the asserted patent expiry dates.
How strong is Noven’s patent estate against Mylan in this litigation?
Strength analysis requires:
- Claim construction outcomes (Markman rulings).
- Summary judgment on infringement/validity.
- Final merits determinations.
Those records are not included in the provided information. A “strength” conclusion cannot be made without the asserted claims, the court’s claim constructions, and the final disposition.
What generic entry risks exist for Mylan after 1:15-cv-00979?
Generic entry risk depends on:
- Whether the case ended in favor of Noven (infringement and/or validity upheld), resulting in continued enforcement and a barrier to launch absent design-around.
- Whether the case ended in favor of Mylan (invalidity/non-infringement), enabling potential launch once any regulatory stays expire.
- Whether a settlement produced a delayed entry date, license terms, or limited launch scope.
No docket outcome, settlement dates, or license terms are present in the provided inputs.
Did Mylan file a Paragraph IV certification in 1:15-cv-00979, and what are the implications?
Paragraph IV certification is typical in disputes like this but cannot be confirmed from the supplied content. If Paragraph IV was asserted, implications include:
- A 30-month stay of FDA approval (subject to triggers like earlier court decisions).
- Use of the “infringement-by-definition” framework for filing-later adjudication.
- Potential later launch timing constrained by appeal, superseding decisions, or settlement.
Confirmation requires the ANDA-linked complaint allegations.
What claim constructions or key legal rulings affected the outcome in 1:15-cv-00979?
Claim construction is usually the central inflection point in infringement disputes. Without the docket orders, no court-level ruling can be stated.
How does this case compare with other Noven vs. generic patent litigations?
A comparative analysis requires:
- Other Noven dockets with the same RLD (or same patent families).
- Shared common patents and repeated infringement theories.
- Consistent procedural outcomes (settlement patterns, typical launch delay lengths).
The provided inputs include only this docket identifier, so comparisons cannot be made with evidence.
What settlement terms or licensing outcomes were reached (if any) in 1:15-cv-00979?
Settlement outcomes are typically reflected by:
- Dismissal without prejudice after license/settlement.
- Consent judgments and entry of permanent injunctions.
- Stipulated dismissal after payment and/or delayed launch.
No settlement terms or dismissal language are included in the provided inputs, so no outcome can be stated.
Key Takeaways
- The docket number 1:15-cv-00979 confirms a branded-versus-generic Hatch-Waxman patent litigation filed in 2015 by Noven against Mylan.
- A litigation summary that is decision-grade requires the asserted patent list and the case’s dispositive outcome, which are not present in the provided inputs.
- Without complaint and judgment/settlement content, no defensible statements can be made on Orange Book status, patent expiry dates, claim constructions, or launch risk timing for Mylan.
FAQs
- How can I determine which specific patents were “patents-in-suit” for Noven vs. Mylan 1:15-cv-00979?
- What did the court’s claim construction do to the infringement analysis in 1:15-cv-00979?
- Did 1:15-cv-00979 trigger a 30-month FDA stay, and when did it end?
- What settlement structure is typical for Noven-brand cases in Hatch-Waxman, and what would it mean for Mylan’s launch?
- How should analysts translate a final judgment in an ANDA patent case into design-around and marketing-entry timelines?
References
- Federal case docket identifier: Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., No. 1:15-cv-00979 (U.S. District Court).
